| Serial Number | 98130731 |
| Word Mark | ZYGEL |
| Filing Date | Monday, August 14, 2023 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Tuesday, October 7, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Indication of Colors claimed | The color(s) purple, yellow, orange and red is/are claimed as a feature of the mark. |
| Description of Mark | The mark consists of the word "ZYGEL" in purple stylized text to the left of an arrangement of vertical and horizontal, yellow and orange rectangles with rounded ends featuring three purple teardrop shapes and two red teardrop shapes within a grid pattern created by the rectangles. |
| Goods and Services | Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders and all of the foregoing solely derived from manufactured synthetic cannabidiol and which do not contain delta-9 tetrahydrocannabinol (THC) |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, September 13, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Zynerba Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Devon, PA 19333 |
| Event Date | Event Description |
| Thursday, August 17, 2023 | NEW APPLICATION ENTERED |
| Wednesday, September 13, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 14, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, September 20, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, September 27, 2023 | ASSIGNED TO EXAMINER |
| Monday, October 2, 2023 | ASSIGNED TO EXAMINER |
| Friday, January 5, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, January 5, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, January 5, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, March 11, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 11, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 11, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, October 7, 2025 | NON-FINAL ACTION WRITTEN |
| Tuesday, October 7, 2025 | NON-FINAL ACTION E-MAILED |
| Tuesday, October 7, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 30, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Thursday, October 30, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |